Which has grown faster, BFRI or CTSO?

Over the past five years, BFRI grew revenue faster — BFRI at a 15.55% CAGR versus CTSO at -3.17%.

Biofrontera Inc. (BFRI) vs Cytosorbents Corporation (CTSO)

A side-by-side comparison of Biofrontera Inc. and Cytosorbents Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BFRI

Biofrontera Inc.

$12M

$0.93HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

CTSO

Cytosorbents Corporation

$12M

$3.96HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BFRI vs CTSO

growth of $100 · dividends reinvested · last 5y

BFRI -99.0% (-60.1%/yr)CTSO -96.6% (-49.2%/yr)CTSO compounded faster over this window

BFRI CTSO

BFRI vs CTSO: by the numbers

•CTSO is the larger company ($12M vs $12M market cap).
•Both run net losses; BFRI's is the smaller (-13.78% vs -48.94% net margin).
•BFRI grew revenue faster over the past five years (15.55% vs -3.17% CAGR).

Metrics side by side

Valuation

Metric	BFRI	CTSO
P/S ratio	0.26	0.33
P/B ratio	2.00	N/A

Profitability

Metric	BFRI	CTSO
Gross margin	84.45%	71.61%
Operating margin	-21.94%	-33.37%
Net margin	-13.78%	-48.94%
ROE	-106.87%	N/A
ROIC	-32.27%	-43.31%

Growth (annualized)

Metric	BFRI	CTSO
Revenue CAGR (5Y)	15.55%	-3.17%
Total return CAGR (5Y)	N/A	-52.26%

Frequently asked

Which has grown faster, BFRI or CTSO?: Over the past five years, BFRI grew revenue faster — BFRI at a 15.55% CAGR versus CTSO at -3.17%.

Go deeper

Full BFRI analysis Full CTSO analysis Interactive comparison tool

Dig into the metrics

Biofrontera ROE Cytosorbents ROE Biofrontera operating margin Cytosorbents operating margin Biofrontera revenue growth Cytosorbents revenue growth Biofrontera free cash flow Cytosorbents free cash flow

Biofrontera & Cytosorbents appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.